Andrea B. Parker
Corporate Officer/Principal at CARDIOL THERAPEUTICS INC.
Andrea B. Parker active positions
Companies | Position | Start | End |
---|---|---|---|
CARDIOL THERAPEUTICS INC. | Corporate Officer/Principal | 2019-06-30 | - |
Career history of Andrea B. Parker
Former positions of Andrea B. Parker
Companies | Position | Start | End |
---|---|---|---|
Toronto General Hospital
Toronto General Hospital Hospital/Nursing ManagementHealth Services Toronto General Hospital provides health care service. Its programs include medical and community care, multi-organ transplant, peter munk cardiac centre, surgery and critical care. The company was founded in and is headquartered in Toronto, Canada. | Corporate Officer/Principal | 2009-12-31 | 2018-12-31 |
Peter Munk Cardiac Centre | Chief Tech/Sci/R&D Officer | 2010-06-30 | 2018-12-31 |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Chief Tech/Sci/R&D Officer | 2002-12-31 | 2005-12-31 |
SOCAR Research SA
SOCAR Research SA BiotechnologyHealth Technology SOCAR Research SA provides clinical research services. It provides services in the areas which include cardiovascular and related, cachexia, hematology, hypertension, metabolic, nephrology, nutraceuticals and oncology telemedicine. The firm's technology include e-SOCDAT is an e-clinical solution which provides e-design, e-data and e-data services. It serves the biotechnology, consumer healthcare, medical device, pharmaceutical, contract research organization and academic institutions. The company was founded in 1986 and is headquartered in Nyon, Switzerland. | Corporate Officer/Principal | 1988-12-31 | 2000-12-31 |
Contract Research Organization | Corporate Officer/Principal | - | - |
CNP Therapeutics, Inc.
CNP Therapeutics, Inc. Medical SpecialtiesHealth Technology CNP Therapeutics, Inc. manufactures medical systems for chronic pain, depression and anxiety. The company was founded by Frank Prato and Alex Thomas on September 16, 1998 and is headquartered in Mississauga, Canada. | Chief Tech/Sci/R&D Officer | - | - |
Training of Andrea B. Parker
University of Toronto | Doctorate Degree |
Universität Leipzig | Graduate Degree |
Harvard T.H. Chan School of Public Health | Graduate Degree |
Statistics
International
Canada | 7 |
United States | 3 |
Switzerland | 2 |
Operational
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Graduate Degree | 2 |
Sectoral
Health Technology | 5 |
Consumer Services | 4 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
CARDIOL THERAPEUTICS INC. | Health Technology |
Private companies | 6 |
---|---|
CNP Therapeutics, Inc.
CNP Therapeutics, Inc. Medical SpecialtiesHealth Technology CNP Therapeutics, Inc. manufactures medical systems for chronic pain, depression and anxiety. The company was founded by Frank Prato and Alex Thomas on September 16, 1998 and is headquartered in Mississauga, Canada. | Health Technology |
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
SOCAR Research SA
SOCAR Research SA BiotechnologyHealth Technology SOCAR Research SA provides clinical research services. It provides services in the areas which include cardiovascular and related, cachexia, hematology, hypertension, metabolic, nephrology, nutraceuticals and oncology telemedicine. The firm's technology include e-SOCDAT is an e-clinical solution which provides e-design, e-data and e-data services. It serves the biotechnology, consumer healthcare, medical device, pharmaceutical, contract research organization and academic institutions. The company was founded in 1986 and is headquartered in Nyon, Switzerland. | Health Technology |
Toronto General Hospital
Toronto General Hospital Hospital/Nursing ManagementHealth Services Toronto General Hospital provides health care service. Its programs include medical and community care, multi-organ transplant, peter munk cardiac centre, surgery and critical care. The company was founded in and is headquartered in Toronto, Canada. | Health Services |
Peter Munk Cardiac Centre | |
Contract Research Organization |
- Stock Market
- Insiders
- Andrea B. Parker
- Experience